Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma.

Coroiu A, Moran C, Bergeron C, Drapeau M, Wang B, Kezouh A, Ernst J, Batist G, Körner A.

BMC Cancer. 2020 Feb 14;20(1):123. doi: 10.1186/s12885-019-6476-5.

2.

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.

Couëtoux du Tertre M, Marques M, McNamara S, Gambaro K, Hoffert C, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, McIntosh L, Hindie V, Parent S, Cortes L, Breton YA, Pottiez G, Croteau P, Higenell V, Izzi L, Spatz A, Cohen V, Batist G, Agulnik J.

Clin Proteomics. 2020 Feb 7;17:5. doi: 10.1186/s12014-020-9269-6. eCollection 2020.

3.

Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data.

Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, Batist G, Borchers CH.

Cancers (Basel). 2019 Dec 1;11(12). pii: E1907. doi: 10.3390/cancers11121907.

4.

Targeted and Untargeted Proteomics Approaches in Biomarker Development.

Sobsey CA, Ibrahim S, Richard VR, Gaspar V, Mitsa G, Lacasse V, Zahedi RP, Batist G, Borchers CH.

Proteomics. 2019 Nov 15:e1900029. doi: 10.1002/pmic.201900029. [Epub ahead of print] Review.

PMID:
31729135
5.

Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report.

Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, Batist G, Basik M.

Front Oncol. 2019 Aug 6;9:698. doi: 10.3389/fonc.2019.00698. eCollection 2019.

6.

Multiplexed real-time polymerase chain reaction cell-free DNA assay as a potential method to monitor stage IV colorectal cancer.

Sinha S, Brown H, Tabak J, Fang Z, Tertre MCD, McNamara S, Gambaro K, Batist G, Buell JF.

Surgery. 2019 Oct;166(4):534-539. doi: 10.1016/j.surg.2019.06.004. Epub 2019 Aug 1.

PMID:
31378479
7.

Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.

Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, Batist G, Agulnik J.

Mol Cancer Ther. 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26.

PMID:
31243098
8.

A network approach to developing immuno-oncology combinations in Canada.

Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S.

Curr Oncol. 2019 Apr;26(2):73-79. doi: 10.3747/co.26.4393. Epub 2019 Apr 1.

9.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R.

Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.

10.

Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada.

Batist G, Michaud S, Richards DP, Servidio-Italiano F, Stein BD.

Curr Oncol. 2018 Dec;25(6):e597-e609. doi: 10.3747/co.25.4213. Epub 2018 Dec 1.

11.

Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer.

Aubin S, Rosberger Z, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, Kavan P.

J Adolesc Young Adult Oncol. 2019 Apr;8(2):172-189. doi: 10.1089/jayao.2017.0101. Epub 2018 Nov 28.

PMID:
30484730
12.

A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.

Alcaide M, Cheung M, Bushell K, Arthur SE, Wong HL, Karasinska J, Renouf D, Schaeffer DF, McNamara S, Tertre MCD, Batist G, Kennecke HF, Karsan A, Morin RD.

J Mol Diagn. 2019 Mar;21(2):214-227. doi: 10.1016/j.jmoldx.2018.09.007. Epub 2018 Nov 23.

13.

Co-Incidence of Epstein-Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women.

Al-Thawadi H, Ghabreau L, Aboulkassim T, Yasmeen A, Vranic S, Batist G, Al Moustafa AE.

Front Oncol. 2018 Jul 2;8:250. doi: 10.3389/fonc.2018.00250. eCollection 2018.

14.

Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry.

Mnatsakanyan R, Shema G, Basik M, Batist G, Borchers CH, Sickmann A, Zahedi RP.

Expert Rev Proteomics. 2018 Jun;15(6):515-535. doi: 10.1080/14789450.2018.1483340.

PMID:
29893147
15.

Effect of cell-phone radiofrequency on angiogenesis and cell invasion in human head and neck cancer cells.

Alahmad YM, Aljaber M, Saleh AI, Yalcin HC, Aboulkassim T, Yasmeen A, Batist G, Moustafa AA.

Head Neck. 2018 Oct;40(10):2166-2171. doi: 10.1002/hed.25210. Epub 2018 May 13.

PMID:
29756334
16.

How iMALDI can improve clinical diagnostics.

Popp R, Basik M, Spatz A, Batist G, Zahedi RP, Borchers CH.

Analyst. 2018 May 15;143(10):2197-2203. doi: 10.1039/c8an00094h. Review.

PMID:
29713694
17.

The importance of greater speed in drug development for advanced malignancies.

Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R.

Cancer Med. 2018 May;7(5):1824-1836. doi: 10.1002/cam4.1454. Epub 2018 Mar 30.

18.

[Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria].

Felfoul O, Mohammadi M, Taherkhani S, de Lanauze D, Zhong Xu Y, Lafleur M, Gaboury L, Tabrizian M, Vuong T, Batist G, Beauchemin N, Radzioch D, Martel S.

Med Sci (Paris). 2018 Mar;34(3):197-199. doi: 10.1051/medsci/20183403002. Epub 2018 Mar 16. French. No abstract available.

19.

Elaeagnus angustifolia Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation.

Saleh AI, Mohamed I, Mohamed AA, Abdelkader M, Yalcin HC, Aboulkassim T, Batist G, Yasmeen A, Moustafa AA.

Nutr Cancer. 2018 Feb-Mar;70(2):297-305. doi: 10.1080/01635581.2018.1412472. Epub 2018 Jan 4.

PMID:
29300111
20.

Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes.

Kasymjanova G, Small D, Cohen V, Jagoe RT, Batist G, Sateren W, Ernst P, Pepe C, Sakr L, Agulnik J.

Curr Oncol. 2017 Oct;24(5):302-309. doi: 10.3747/co.24.3611. Epub 2017 Oct 25.

21.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

22.

Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits.

Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD.

Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.

23.

Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors.

Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, Basik M, Batist G, Borchers CH.

Anal Chem. 2017 Oct 3;89(19):10592-10600. doi: 10.1021/acs.analchem.7b02934. Epub 2017 Sep 20.

PMID:
28853539
24.

The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.

Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M.

Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.

25.

Substantial Toxic Effect of Water-Pipe Smoking on the Early Stage of Embryonic Development.

Ashour AA, Haik MY, Sadek KW, Yalcin HC, Bitharas J, Aboulkassim T, Batist G, Yasmeen A, Al Moustafa AE.

Nicotine Tob Res. 2018 Mar 6;20(4):502-507. doi: 10.1093/ntr/ntx135.

PMID:
28605482
26.

Toward Implementing Patient Flow in a Cancer Treatment Center to Reduce Patient Waiting Time and Improve Efficiency.

Suss S, Bhuiyan N, Demirli K, Batist G.

J Oncol Pract. 2017 Jun;13(6):e530-e537. doi: 10.1200/JOP.2016.020008. Epub 2017 May 4.

PMID:
28471694
27.

Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study.

Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, Batist G, Azoulay L, Kavan P.

Clin Colorectal Cancer. 2017 Dec;16(4):334-342. doi: 10.1016/j.clcc.2017.03.008. Epub 2017 Mar 21.

PMID:
28462853
28.

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.

Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL.

Medicine (Baltimore). 2017 Apr;96(16):e6544. doi: 10.1097/MD.0000000000006544.

29.

Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions.

Felfoul O, Mohammadi M, Taherkhani S, de Lanauze D, Zhong Xu Y, Loghin D, Essa S, Jancik S, Houle D, Lafleur M, Gaboury L, Tabrizian M, Kaou N, Atkin M, Vuong T, Batist G, Beauchemin N, Radzioch D, Martel S.

Nat Nanotechnol. 2016 Nov;11(11):941-947. doi: 10.1038/nnano.2016.137. Epub 2016 Aug 15.

30.

Nrf2 Transcription Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY.

Bendavit G, Aboulkassim T, Hilmi K, Shah S, Batist G.

J Biol Chem. 2016 Dec 2;291(49):25476-25488. Epub 2016 Oct 26.

31.

A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.

Paquet ER, Cui J, Davidson D, Pietrosemoli N, Hassan HH, Tsofack SP, Maltais A, Hallett MT, Delorenzi M, Batist G, Aloyz R, Lebel M.

J Pathol Clin Res. 2015 Apr 9;1(3):160-72. doi: 10.1002/cjp2.17. eCollection 2015 Jul.

32.

Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting.

Mamo A, Easaw J, Ibnshamsah F, Baig A, Rho YS, Kavan T, Batist G, Kavan P.

Curr Oncol. 2016 Jun;23(3):171-7. doi: 10.3747/co.23.3059. Epub 2016 Jun 9.

33.

Identification of performance indicators across a network of clinical cancer programs.

Khare SR, Batist G, Bartlett G.

Curr Oncol. 2016 Apr;23(2):81-90. doi: 10.3747/co.23.2789. Epub 2016 Apr 13.

34.

Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer.

Al Moustafa AE, Al-Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1936-9. doi: 10.1080/21645515.2016.1139255. Epub 2016 Apr 15.

35.

Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.

McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, Kavan P.

Clin Colorectal Cancer. 2016 Jun;15(2):135-40. doi: 10.1016/j.clcc.2015.10.003. Epub 2015 Oct 21.

PMID:
26553578
36.

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases.

Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R.

Clin Cancer Res. 2015 Oct 15;21(20):4561-8. doi: 10.1158/1078-0432.CCR-14-3246.

37.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

38.

Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study.

Aboulkassim T, Yasmeen A, Akil N, Batist G, Al Moustafa AE.

Hum Vaccin Immunother. 2015;11(4):951-5. doi: 10.1080/21645515.2015.1009342.

39.

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R.

Ann Oncol. 2015 Aug;26(8):1791-8. doi: 10.1093/annonc/mdv191. Epub 2015 Apr 23.

40.

Advances in the approach to novel drug clinical development for breast cancer.

Ferrario C, Batist G.

Expert Opin Drug Discov. 2014 Jun;9(6):647-68. doi: 10.1517/17460441.2014.911282. Epub 2014 Apr 23. Review.

PMID:
24758225
41.

Redefining cancer: a new paradigm for better and faster treatment innovation.

Stewart DJ, Batist G.

J Popul Ther Clin Pharmacol. 2014;21(1):e56-65. Epub 2014 Feb 23.

PMID:
24671868
42.

The relationship of self-rated health with functional status, toxicity and mortality: results of a prospective pilot study of older patients with newly-diagnosed cancer.

Puts M, Monette J, Girre V, Sourial N, Wolfson C, Monette M, Batist G, Bergman H.

J Geriatr Oncol. 2013 Oct;4(4):319-26. doi: 10.1016/j.jgo.2013.07.003. Epub 2013 Aug 12.

PMID:
24472474
43.

Imiquimod in the treatment of breast cancer skin metastasis.

Henriques L, Palumbo M, Guay MP, Bahoric B, Basik M, Kavan P, Batist G.

J Clin Oncol. 2014 Mar 10;32(8):e22-5. doi: 10.1200/JCO.2012.46.4883. Epub 2014 Jan 13. No abstract available.

PMID:
24419128
44.

Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis.

Chukkapalli S, Amessou M, Dekhil H, Dilly AK, Liu Q, Bandyopadhyay S, Thomas RD, Bejna A, Batist G, Kandouz M.

Carcinogenesis. 2014 Apr;35(4):877-85. doi: 10.1093/carcin/bgt399. Epub 2013 Dec 4.

PMID:
24306026
45.

Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells.

Chukkapalli S, Amessou M, Dilly AK, Dekhil H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA, Neill D, Azoulay L, Batist G, Kandouz M.

Exp Cell Res. 2014 Jan 15;320(2):233-46. doi: 10.1016/j.yexcr.2013.10.022. Epub 2013 Nov 6.

PMID:
24211352
46.

Use of statins and the risk of death in patients with prostate cancer.

Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L.

J Clin Oncol. 2014 Jan 1;32(1):5-11. doi: 10.1200/JCO.2013.49.4757. Epub 2013 Nov 4.

PMID:
24190110
47.

Benefits, issues, and recommendations for personalized medicine in oncology in Canada.

Butts C, Kamel-Reid S, Batist G, Chia S, Blanke C, Moore M, Sawyer MB, Desjardins C, Dubois A, Pun J, Bonter K, Ashbury FD.

Curr Oncol. 2013 Oct;20(5):e475-83. doi: 10.3747/co.20.1253.

48.

Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009.

Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P.

Curr Oncol. 2013 Oct;20(5):247-51. doi: 10.3747/co.20.1370.

49.

Biopsies: next-generation biospecimens for tailoring therapy.

Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G.

Nat Rev Clin Oncol. 2013 Aug;10(8):437-50. doi: 10.1038/nrclinonc.2013.101. Epub 2013 Jun 25. Review. Erratum in: Nat Rev Clin Oncol. 2013 Nov;10(11):608.

PMID:
23799370
50.

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.

Diaz Z, Aguilar-Mahecha A, Paquet ER, Basik M, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, Lespérance B, Samson B, Kavan P, Alcindor T, Dalfen R, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, Spatz A, Têtu B, Batist G.

Mod Pathol. 2013 Nov;26(11):1413-24. doi: 10.1038/modpathol.2013.81. Epub 2013 Jun 7.

Supplemental Content

Loading ...
Support Center